Nuvectis Pharma, Inc. (NVCT)
After hours:
| Previous Close | 6.40 |
| Open | 6.59 |
| Bid | 6.64 x 100 |
| Ask | 6.90 x 100 |
| Day's Range | 6.20 - 6.87 |
| 52 Week Range | 5.85 - 18.65 |
| Volume | |
| Avg. Volume | 95,582 |
| Market Cap | 124.271M |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.41 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.00 |
ZacksWall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 229.3% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewswireNuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City. Event H.C. W
- GuruFocus.com
Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes
Performance Analysis and Future Outlook Amidst Clinical Progress
